Personalis to Participate at the 6th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

Rhea-AI Summary

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced cancer genomics, announced its participation in the 6th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 17, 2021. The company specializes in population sequencing and cancer genomics, focusing on providing comprehensive molecular data from a single tissue sample through the Personalis® ImmunoID NeXT Platform®. Additionally, Personalis is the sole sequencing provider to the VA MVP, emphasizing its commitment to quality and efficiency in oncology.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the 6^th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 17, 2021.

About Personalis, Inc.

Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the VA MVP. In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing Personalis’ biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis’ Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

View source version on businesswire.com: https://www.businesswire.com/news/home/20210803005158/en/

FAQ

When is Personalis participating in the Needham Virtual MedTech & Diagnostics Conference?

Personalis will participate in the conference on August 17, 2021.

What is the focus of Personalis, Inc.?

Personalis focuses on advanced genomics and population sequencing for cancer.

What is the Personalis ImmunoID NeXT Platform?

It provides comprehensive molecular data about cancer and the immune response from a single tissue sample.

Who is the sole sequencing provider to the VA MVP?

Personalis, Inc. is the sole sequencing provider to the VA MVP.

What certifications does Personalis' Clinical Laboratory hold?

The Clinical Laboratory is GxP aligned, CLIA’88-certified, and CAP-accredited.